It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores. ...

Figure 1 MD Projects-Eeyou Istchee James Bay Figure 2 Caniaspic Au 2025 Results Figure 3 Caniapisc Au Planned IP Figure 4 Samples 2025 Figure 5 Samples 2025 Figure 6 Samples 2025 MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce the start of an induced polarization ground (“IP’) geophysical survey on its Caniapisc Au project, in the Eeyou Istchee James Bay and Caniapiscau regions. The Caniapisc Au project is wholly ...

CFO Kasandra Rossi said consolidated revenue declined year over year, driven by $26 million of net non-same-unit activity tied to portfolio restructuring, partly offset by acquisition-related and organic growth. On a same-unit basis, the company posted 4% growth , with same-unit pricing up just under 7% and overall patient service volumes down just under 3% .Medtronic’s “Textbook” Reversal: How High Can It Really Go in 2026?CEO Mark Ordan said adjusted EBITDA was $66 million in the fourth quarter, “in line ...

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology. ...

Key Takeaways Pediatrix Medical Group's Q4 EPS of 50 cents missed estimates as revenues fell 1.7% year over year.MD saw 4% same-unit revenue growth, driven by 6.7% gains in reimbursement-related factors.MD sees 2026 EBITDA outlook at $280-$300M and repurchased 4.1M shares in 2025.Pediatrix Medical Group, Inc. (MD) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 50 cents, which missed the Zacks Consensus Estimate by 4.9%. The bottom line declined 2% year over year.Net revenues decreased 1.7 ...

Pediatrix Medical Group (NYSE: MD) wasn't one of the healthier stocks on the U.S. market on Thursday. The healthcare services provider's shares fell by more than 12% over the course of the day, due mostly to the earnings report it published early that morning. Double dips In its fourth quarter, Pediatrix's revenue came in at nearly $493.8 million, down almost 2% year over year. Net income not in accordance with generally accepted accounting principles (GAAP) also dipped slightly, falling to $42.5 million ...

Financial Data and Key Metrics Changes - The adjusted EBITDA for Q4 2025 was $66 million, aligning with the upwardly adjusted guidance, while the full-year adjusted EBITDA reached $276 million [5][6] - The consolidated revenue decreased due to net non-same-unit activity of $26 million, but same-unit growth was 4% with pricing up just under 7% [7][8] - Operating cash flow for Q4 was $115 million, down from $135 million in the prior year, primarily due to decreases in cash flow from accounts payable and accrued liabilities [9] Business Line Data and Key Metrics Changes - Patient service volumes decreased by just under 3%, with NICU days down about 2% [7][8] - Despite volume declines across service lines, pricing was driven by solid revenue cycle management cash collections and favorable payer mix [7][8] Market Data and Key Metrics Changes - The company anticipates full-year revenue for 2026 to be approximately $1.9 billion, in line with 2025 [10] - The G&A expense for 2026 is projected to be between $230 million and $240 million, compared to $241 million in 2025 [10] Company Strategy and Development Direction - The company is focusing on quality care and has introduced new programs to align physicians with the organization, including cash bonuses and stock price tracking elements [12][13] - There are plans to leverage telemedicine and expand in NICUs and maternal-fetal medicine, with a strong presence in OB hospital medicine [14][15] Management's Comments on Operating Environment and Future Outlook - Management expects steady metrics for 2026, including volume, acuity, and payer mix, with a preliminary outlook of adjusted EBITDA between $280 million and $300 million [6][10] - The company is monitoring potential impacts from ACA subsidies and government enrollment changes, but currently sees no significant changes in payer mix [29][30] Other Important Information - The company ended Q4 with cash of $375 million and net debt of just over $220 million, reflecting a net leverage of just under 1x [9] - The company has not factored any contributions from M&A activity into the 2026 guidance but is open to opportunities that align with its core strengths [11][41] Q&A Session Summary Question: Drivers of revenue growth for 2026 - Management indicated that the revenue growth assumes flat volume and pricing, with no significant changes expected [18] Question: Reasons for negative patient volume year-over-year - The decrease in volume was attributed to tough comparisons from the previous year's fourth quarter [20] Question: Details on variable compensation expenses - Management noted that various factors influenced fourth-quarter operations, emphasizing alignment with physicians rather than smoothing effects [26] Question: Insights on pricing strength and sustainability - Pricing was up just under 7%, driven by strong RCM collections and favorable payer mix, with expectations for stability moving into 2026 [47][50]

Financial Data and Key Metrics Changes - The adjusted EBITDA for Q4 2025 was $66 million, aligning with the upwardly adjusted guidance, while the full-year adjusted EBITDA reached $276 million [5][6] - The company expects 2026 adjusted EBITDA to be in the range of $280 million to $300 million, representing a 5% increase from 2025 [6][10] - Consolidated revenue decreased due to net non-same-unit activity of $26 million, but same-unit growth was 4% with pricing up just under 7% [7][10] Business Line Data and Key Metrics Changes - Patient service volumes decreased by just under 3%, with NICU days down about 2% [7][8] - Variable practice incentive compensation and salary and benefits increased on a same-unit basis, while G&A expenses rose year-over-year due to salary and travel expenses [8][9] Market Data and Key Metrics Changes - The company ended Q4 with cash of $375 million and net debt of just over $220 million, reflecting a net leverage of just under 1x [9] - The accounts receivable days sales outstanding (AR DSO) improved to 42.8 days, down almost five days year-over-year [9] Company Strategy and Development Direction - The company introduced new programs to align physicians with cash bonuses and stock price tracking elements, aiming to enhance care quality and organizational alignment [12][13] - Pediatrix is focusing on leveraging telemedicine and expanding its presence in OB hospital medicine, with plans for growth in NICUs and maternal-fetal medicine [13][15] Management's Comments on Operating Environment and Future Outlook - Management noted that the operating environment remains stable, with expectations for steady metrics in 2026, although potential impacts from ACA subsidies are acknowledged [6][10] - The company is committed to maintaining its balance sheet strength and will only consider growth opportunities that do not dilute its core pediatrics and obstetrics strengths [15][41] Other Important Information - The company plans to update on potential M&A activity in 2026, with a focus on maintaining its core strengths while exploring growth opportunities [11][41] Q&A Session Summary Question: Drivers of revenue growth for 2026 - Management indicated that revenue growth is expected to be flat in both volume and pricing for 2026 [18][19] Question: Reasons for negative patient volume year-over-year - Management attributed the decline in patient volume to tough comparisons from Q4 of the previous year [20][21] Question: Details on variable compensation expenses - Management noted that various factors influenced Q4 operations, emphasizing alignment rather than smoothing effects for future years [25][26] Question: Guidance on pricing and payer mix - Management confirmed that pricing is expected to remain steady, with no significant changes anticipated in payer mix for 2026 [30][31] Question: G&A cost reduction assumptions - Management acknowledged a small expected decline in G&A expenses year-over-year, with no specific factors identified [37][38] Question: Share repurchase plans - Management indicated a smaller amount of stock buyback is anticipated in the current guidance compared to 2025 [39][40] Question: Sustainability of pricing strength - Management highlighted strong RCM collections and favorable payer mix as key drivers of pricing strength, with expectations for stability moving into 2026 [45][46]

Financial Data and Key Metrics Changes - The adjusted EBITDA for Q4 2025 was $66 million, aligning with the upwardly adjusted guidance, while the full-year adjusted EBITDA reached $276 million [4] - The company expects 2026 adjusted EBITDA to be in the range of $280 million to $300 million, representing a 5% increase from 2025 [5] - Consolidated revenue decreased due to net non-same-unit activity of $26 million, but same-unit growth was 4% with same-unit pricing up just under 7% [6][9] Business Line Data and Key Metrics Changes - Patient service volumes decreased by just under 3%, with NICU days down about 2% [6] - Variable practice incentive compensation and salary and benefits increased on a same-unit basis, while salary growth for Q4 was modestly below the previous six-quarter average of around 3% [7] Market Data and Key Metrics Changes - The company ended Q4 with cash of $375 million and net debt of just over $220 million, reflecting a net leverage of just under 1x [8] - The accounts receivable days sales outstanding (AR DSO) improved to 42.8 days, down almost 5 days year-over-year due to better cash collections [8] Company Strategy and Development Direction - The company is focusing on quality care and has introduced new programs to align physicians with the company's goals, including cash bonuses and stock price tracking elements [11] - There are plans to leverage telemedicine and expand in NICUs and maternal-fetal medicine, with a strong presence in OB hospital medicine [12][13] - The company aims to maintain its balance sheet strength while exploring growth opportunities without diluting its core pediatrics and obstetrics focus [13][14] Management's Comments on Operating Environment and Future Outlook - Management noted that the decrease in patient volume was primarily due to tough comparisons from the previous year [20] - The company is closely monitoring potential impacts from ACA subsidies and payer mix changes, but currently sees no significant changes [28][30] - The guidance for 2026 assumes steady metrics similar to those in 2025, with no significant changes expected [33] Other Important Information - The company has not factored in any contributions from M&A activity in 2026 but is open to opportunities that align with its core strengths [10][41] - The company anticipates a decline in G&A expenses for 2026, forecasting them to be in the range of $230 million to $240 million [9] Q&A Session Summary Question: Drivers of revenue growth for 2026 - Management expects flat volume and pricing for 2026, with no significant changes anticipated [18] Question: Reasons for negative patient volume year-over-year - The decrease in volume was attributed to tough comparisons from the previous year's fourth quarter [20] Question: Details on variable compensation expenses - Management indicated that alignment with physicians is a key driver, rather than smoothing effects [25] Question: Guidance on pricing and payer mix - Management expects pricing to remain steady, with some favorable payer mix observed in 2025 [30] Question: Insights on G&A cost reductions - Management noted a small expected decline in G&A expenses, with no specific factors driving this [36] Question: Share repurchase plans - Management anticipates a smaller amount of stock buyback compared to 2025 [38] Question: Growth opportunities and potential M&A - Management is exploring various growth avenues, including telemedicine and physical practices, while being cautious about M&A that could dilute core strengths [39][41]

Pediatrix Medical Group (MD) came out with quarterly earnings of $0.5 per share, missing the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.94%. A quarter ago, it was expected that this physician group would post earnings of $0.46 per share when it actually produced earnings of $0.67, delivering a surprise of +45.65%.Over the last four quarters ...